Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Micronutrient Powder Programs: New Findings and Future Directions for Implementation Science.

Pelletier D, DePee S.

Matern Child Nutr. 2019 Mar 3:e12802. doi: 10.1111/mcn.12802. [Epub ahead of print] No abstract available.

PMID:
30828965
2.

Longitudinal assessment of associations between food insecurity, antiretroviral adherence and HIV treatment outcomes in rural Uganda.

Weiser SD, Palar K, Frongillo EA, Tsai AC, Kumbakumba E, Depee S, Hunt PW, Ragland K, Martin J, Bangsberg DR.

AIDS. 2014 Jan 2;28(1):115-20. doi: 10.1097/01.aids.0000433238.93986.35.

3.

Program experience with micronutrient powders and current evidence.

Rah JH, dePee S, Kraemer K, Steiger G, Bloem MW, Spiegel P, Wilkinson C, Bilukha O.

J Nutr. 2012 Jan;142(1):191S-6S. doi: 10.3945/jn.111.140004. Epub 2011 Nov 30. Review.

PMID:
22131547
4.

Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats.

Conway JG, Pink H, Bergquist ML, Han B, Depee S, Tadepalli S, Lin P, Crumrine RC, Binz J, Clark RL, Selph JL, Stimpson SA, Hutchins JT, Chamberlain SD, Brodie TA.

J Pharmacol Exp Ther. 2008 Jul;326(1):41-50. doi: 10.1124/jpet.107.129429. Epub 2008 Apr 23.

PMID:
18434589
5.

Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.

Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E, Jansen M, Lin P, Payne A, Crosby RM, Johnson JH, Frick L, Lin MH, Depee S, Tadepalli S, Votta B, James I, Fuller K, Chambers TJ, Kull FC, Chamberlain SD, Hutchins JT.

Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16078-83. Epub 2005 Oct 25.

6.

A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.

Paz-Ares L, Kunka R, DeMaria D, Cassidy J, Alden M, Beranek P, Kaye S, Littlefield D, Reilly D, Depee S, Wissel P, Twelves C, O'Dwyer P.

Br J Cancer. 1998 Nov;78(10):1329-36.

7.

Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.

Eckhardt SG, Baker SD, Eckardt JR, Burke TG, Warner DL, Kuhn JG, Rodriguez G, Fields S, Thurman A, Smith L, Rothenberg ML, White L, Wissel P, Kunka R, DePee S, Littlefield D, Burris HA, Von Hoff DD, Rowinsky EK.

Clin Cancer Res. 1998 Mar;4(3):595-604.

8.

The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.

Gerrits CJ, Schellens JH, Creemers GJ, Wissel P, Planting AS, Pritchard JF, DePee S, de Boer-Dennert M, Harteveld M, Verweij J.

Br J Cancer. 1997;76(7):946-51.

9.

Determination of GI147211 in human blood by HPLC with fluorescence detection.

Selinger K, Smith G, Depee S, Aureche C.

J Pharm Biomed Anal. 1995 Nov;13(12):1521-30.

PMID:
8788138

Supplemental Content

Support Center